ASSOCATION OF SERUM SEX HORMONE BINDING GLOBULIN WITH TYPE 2 DIABETES MELLITUS
Sex Hormone Binding Globulin And Diabetes Mellitus
Objective: To investigate the association of circulating levels of sex hormone binding globulin with type 2 diabetes mellitus.
Study Design: Case control study.
Place and Duration of Study: The study was conducted at the Department of Chemical Pathology, Army Medical College Rawalpindi.
Material and Methods: This study consisted of two groups; A and B. Group A consisted of type 2 diabetic patients and group B consisted of healthy controls. Each group comprised of 60 participants which were randomly selected from Endocrinology Department of Military Hospital (MH), Rawalpindi. Fasting blood samples of the participants were analyzed for serum sex hormone binding globulin (SHBG), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c) and fasting insulin levels. The biochemical analysis was carried out at the Chemical Pathology Department, Army Medical College Rawalpindi. The data obtained were statistically analyzed with SPSS version 20.
Results: In this study, low levels of SHBG (39.53 ± 22.25 vs. 62.35 ± 32.52, p=<0.05) were noted in diabetic as compared to the control participants. The diabetic patients presented with significantly higher fasting plasma glucose (11.23 ± 3.65 vs. 4.35 ± 0.68, p=<0.05), HbA1c (6.84 ± 0.48 vs. 5.31 ± 0.48, p=<0.05), serum insulin (8.90 ± 6.51 vs. 6.32 ± 4.09, p=<0.05) and insulin resistance (4.84 ± 5.18 vs. 1.23 ± 0.83, p=<0.05), calculated by HOMA-IR. SHBG was negatively associated with HbA1c (r-0.101), FPG (r -0.107), serum insulin (r-0.132) and insulin resistance, IR (-0.142) in the diabetic group.
Conclusion: This study concludes that SHBG levels are markedly decreased in type 2 diabetes mellitus. Therefore, SHBG has a potential to be used as a biomarker of metabolic control in type 2 diabetes mellitus.